Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity

Recombinant Activated Factor VII for Adjunctive Hemorrhage Control in Trauma

2001 • 455 citations

Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist

2003 • 450 citations

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

2004 • 312 citations

Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors

1997 • 287 citations

Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems

1993 • 272 citations

Adverse drug event monitoring at the food and drug administration

2003 • 251 citations

A postmarketing surveillance program to monitor Ultram® (tramadol hydrochloride) abuse in the United States

1999 • 240 citations

A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors

1998 • 219 citations

Safety of factor VIII inhibitor bypass activity (FEIBA^®): 10‐year compilation of thrombotic adverse events

2002 • 218 citations

Mechanism of factor VIIa–dependent coagulation in hemophilia blood

2002 • 207 citations

The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors

1983 • 182 citations

Introducing MEDWatch

1993 • 174 citations

Safety profile of recombinant factor VIIa

2004 • 168 citations

Treatment of acquired haemophilia with factor eight inhibitor bypassing activity

2004 • 164 citations

FEIBA^®: mode of action

2004 • 162 citations

Spontaneous reporting of adverse drug reactions. I: the data.

1988 • 149 citations

High‐dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia‐like conditions in a cell‐based model system

2001 • 142 citations

Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII

2002 • 138 citations

Recombinant Activated Factor VII for the Rapid Correction of Coagulopathy in Nonhemophilic Neurosurgical Patients

2003 • 137 citations

Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study Group

1990 • 131 citations

Prescription-event monitoring and reporting of adverse drug reactions

2001 • 128 citations

Acute Myocardial Infarction Following Administration of Recombinant Activated Factor VII (Novo Seven) in a Patient with Haemophilia A and Inhibitor

1999 • 113 citations

Renal Failure Associated with the Use of Celecoxib and Rofecoxib

2002 • 111 citations

Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig‐Therasorb)

2001 • 109 citations

Use of Recombinant Factor VIIa in 3 Patients with Inherited Type I Glanzmann’s Thrombasthenia Undergoing Invasive Procedures

2000 • 107 citations

Pancreatitis Associated with Atypical Antipsychotics: From the Food and Drug Administration's MedWatch Surveillance System and Published Reports

2003 • 106 citations

Pharmacovigilance in the pharmaceutical industry

1998 • 92 citations

Inhibitors in hemophilia patients: Current status and management

1994 • 84 citations

Ability of Recombinant Factor VIIa to Generate Thrombin During Inhibition of Tissue Factor in Human Subjects

2001 • 83 citations

Is reporting rate a good predictor of risks associated with drugs?

1999 • 79 citations

Safety, efficacy and lessons from continuous infusion with rFVIIa

1998 • 77 citations

A summary of Food and Drug Administration‐reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole

2003 • 77 citations

Mechanism by which recombinant factor VIIa shortens the aPTT: Activation of factor X in the absence of tissue factor

1989 • 76 citations

Neutrophils express tissue factor in a monkey model of sepsis

2000 • 71 citations

Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.

2000 • 71 citations

Activated prothrombin complex concentrate (FEIBA^®) treatment during surgery in patients with inhibitors to FVIII/IX

2004 • 69 citations

Expression of Tissue Factor in High-Grade Carotid Artery Stenosis

2001 • 68 citations

Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: A break from convention in need of controlled trials

2004 • 63 citations

Use of recombinant factor VIIa in hereditary bleeding disorders

2001 • 63 citations

Possible Synergy between Recombinant Factor VIIa and Prothrombin Complex Concentrate in Hemophilia Therapy

2002 • 62 citations

Temporal Patterns of NSAID Spontaneous Adverse Event Reports

2001 • 59 citations

Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia a patients with inhibitors

1994 • 55 citations

Pulmonary Embolism After Sequential Use of Recombinant Factor VIIa and Activated Prothrombin Complex Concentrate in a Factor VIII Inhibitor Patient

2002 • 54 citations

Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets

2004 • 51 citations

Analysis and results of the recombinant factor VIIa extended-use registry

2003 • 51 citations

Recombinant Factor VIIa in the Treatment of Bleeding

2004 • 48 citations

Acquired haemophilia: experiences with a standardized approach

2001 • 47 citations

Recombinant Factor VIIa in the Treatment of Bleeding

2004 • 44 citations

Adverse Events after Protamine Administration in Patients Undergoing Cardiopulmonary Bypass: Risks and Predictors of Under-Reporting

1998 • 44 citations

Central venous catheter‐related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors

2003 • 39 citations

Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII

2000 • 38 citations

The Treatment of Bleeding in Hemophilic Patients with Inhibitors with Recombinant Factor VIIa

2000 • 36 citations

Recombinant Factor VIIa Is a Pan-hemostatic Agent?

2000 • 35 citations

Update on Novo Nordisk's clinical trial programme on NovoSeven®

2003 • 34 citations

Inhibitors in young boys with haemophilia

2000 • 31 citations

Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation

2004 • 30 citations

Myocardial Infarction Occurring in a Case of Acquired Haemophilia During the Treatment Course with Recombinant Activated Factor VII

2002 • 29 citations

Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate‐related myocardial infarction in patients with haemophilia and inhibitors

2000 • 24 citations

Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion

2002 • 24 citations

A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole

2003 • 23 citations

The Evidence behind Inhibitor Treatment with Recombinant Factor VIIa

2002 • 22 citations

Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate^®): a prospective pharmacovigilance study

2004 • 21 citations

Manifestations of Factor VIII Inhibitor in the Head and Neck

1999 • 12 citations

Acute myocardial infarction complicating therapy with F VIII followed by APCC and rFVIIa in a 26-year-old man with haemophilia A and F VIII inhibitor.

1998 • 9 citations

An appraisal of spontaneous adverse event monitoring.

1992 • 8 citations

Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors

2000 • 6 citations

Untitled

2000 • 5 citations